Pressmeddelanden från 2cureX

CEO Nathaniel Hutley presents a strategic update on 2cureX’s new Website Blog.

2cureX AB (Ticker: 2CUREX) today opens a News Blog on our website (www.

MFN • 29 Aug 2025 13:40

2cureX AB (“2cureX”) hereby publishes the interim report for the first half year of 2025.

The interim report is available as an attached document as well as on the company’s website (https://www.

MFN • 21 Aug 2025 16:10

Improved communication from 2cureX AB

Moving forward we will continuously inform our respected shareholders about matters of importance.

MFN • 11 Jul 2025 21:10

Correction: CEO Nathaniel Hutley presents latest news from 2cureX on July 2nd 2025.

2cureX AB (Ticker: 2CUREX) today announces continued momentum in its strategic execution, with the share price surging more than 1,000% over...

MFN • 02 Jul 2025 13:19

2cureX AB is in the process of securing a strategic collaboration with PreComb Therapeutics AG.

PreComb Therapeutics AG based in Switzerland and 2cureX AB have signed a Letter of Intent (LOI) to explore a strategic alliance that could a...

MFN • 01 Jul 2025 14:25

KOMMUNIKÉ FRÅN ÅRSSTÄMMAN I 2CUREX AB (PUBL)

Protokoll från den ordinarie bolagsstämman 2024 for 2cureX AB (publ), torsdagen 26 juni 2025.

MFN • 27 Jun 2025 22:35

CEO Nathaniel Hutley presents latest news from 2cureX on July 2nd 2025.

2cureX AB (Ticker: 2CUREX) today announces continued momentum in its strategic execution, with the share price surging more than 1,000% over...

MFN • 13 Jun 2025 14:15

KALLELSE TILL ÅRSSTÄMMA I 2CUREX AB (publ).

Aktieägarna i 2cureX AB (publ), 559128-0077, kallas härmed till årsstämma torsdagen den 26 juni 2025 kl.

MFN • 30 May 2025 13:30

PUBLICERING AV ÅRSREDOVISNINGEN FÖR 2CUREX AB (PUBL)

Årsredovisningen för 2024 för 2cureX AB (publ), 559128-0077, offentliggörs härmed.

MFN • 29 May 2025 17:30

2cureX appoints Mangold Fondkommission AB as new Certified Adviser

2cureX AB has entered into an agreement with Mangold Fondkommission AB (“Mangold”) regarding the service as Certified Adviser.

MFN • 22 May 2025 09:15

2cureX Conducts First Direct-to-Patient IndiTreat® Test Under “Operation Twin Code” Strategy

2cureX AB (Ticker: 2CUREX) is proud to announce a historic commercial milestone: the company has successfully sold and initiated delivery of...

MFN • 20 May 2025 10:00

2cureX AB (2CUREX) Launches “Operation Twin Code” with New Investors, Leadership Transition, and Global Roadmap

2cureX AB (Ticker: 2UREX), a leader in functional precision oncology, announces the initiation of an ambitious multi-phase commercial and cl...

MFN • 15 May 2025 17:20

EARLY NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (publ)

The shareholders of 2cureX AB (publ) are hereby informed of the upcoming Annual General Meeting (AGM), which will take place on Thursday, Ju...

MFN • 14 Apr 2025 12:00

2cureX publishes interim report for the second half year of 2024

2cureX AB (“2cureX”) hereby publishes the interim report for the second half year of 2024.

MFN • 27 Feb 2025 13:00

2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE

2cureX has appointed Mangold Fondkommission AB (“Mangold”) as the Company’s liquidity provider.

MFN • 20 Jan 2025 16:00

Correction: 2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE

2cureX has appointed Mangold Fondkommission AB (“Mangold”) as the Company’s liquidity provider.

MFN • 10 Jan 2025 16:00

2CUREX APPOINTS MANGOLD CORPORATE FINANCE TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE

2cureX has appointed Mangold Corporate Finance as the Company’s liquidity provider.

MFN • 10 Jan 2025 14:00

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)

Nedan följer en sammanfattning av det beslut som fattades.

MFN • 18 Dec 2024 19:15

2cureX AB Announces the Appointment of Dan Honeywell as CEO, Ushering in a New Era of commercial expansion of breakthrough precision oncology products

2cureX AB (Nasdaq First North: 2CUREX) proudly announces the appointment of Dan Honeywell as Chief Executive Officer, marking a significant ...

MFN • 16 Dec 2024 13:00

KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB

Aktieägarna i 2cureX AB, org. nr 559128-0077, ("Bolaget") kallas härmed till extra bolagsstämma onsdagen den 18 december 2024.

MFN • 29 Nov 2024 15:00

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)

Nedan följer en sammanfattning av det beslut som fattades.

MFN • 24 Sep 2024 19:45

Invitation to 2cureX Webcast with Q&A on 24 September 2024

2cureX's Executive Management and Board of Directors are pleased to invite you to a webcast on 24 September 2024 at 20:00 CET.

MFN • 09 Sep 2024 12:30

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB (PUBKL)

The shareholders of 2cureX AB (publ) (“2cureX”), org.

MFN • 04 Sep 2024 08:45

2cureX publishes interim report for the first half year of 2024

2cureX AB (“2cureX”) hereby publishes the interim report for the first half year of 2024.

MFN • 22 Aug 2024 13:00

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)

Nedan följer en sammanfattning av de beslut som fattades.

MFN • 12 Jul 2024 18:00

KOMMUNIKÉ FRÅN ÅRSSTÄMMAN I 2CUREX AB (PUBL)

Protokoll från den ordinarie bolagsstämman 2023 for 2cureX AB (publ), måndagen 1 juli 2024.

MFN • 01 Jul 2024 17:35

PUBLICERING AV ÅRSREDOVISNINGEN FÖR 2CUREX AB (PUBL)

Årsredovisningen för 2023 för 2cureX AB (publ), 559128-0077, offentliggörs härmed.

MFN • 28 Jun 2024 15:00

EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)

Aktieägarna i 2cureX AB (publ) ("2cureX"), org.nr 559128-0077, kallas härmed till extra bolagsstämma.

MFN • 26 Jun 2024 16:15

2CUREX APPOINTS OLE THASTRUP AS NEW CEO

2cureX AB (publ), a company pioneering the use of 3D tumoroids for drug sensitivity prediction in cancer patients, is pleased to announce th...

MFN • 18 Jun 2024 13:45

Correction: 2CUREX AB ABORTS DELISTING AND ANNOUNCES DIRECTED SHARE ISSUE TO A PRIVATE INVESTMENT COMPANY AND SALE OF THE SUBSIDIARY 2CUREX A/S

2cureX AB (publ) ("2cureX" or the "Company") today announces the intention to execute a directed issue of 7,500,000 shares at a Volume Weigh...

MFN • 18 Jun 2024 00:05

2CUREX AB ABORTS DELISTING AND ANNOUNCES DIRECTED SHARE ISSUE TO A PRIVATE INVESTMENT COMPANY AND SALE OF THE SUBSIDIARY 2CUREX A/S

2cureX AB (publ) ("2cureX" or the "Company") today announces the intention to execute a directed issue of 7,500,000 shares at a Volume Weigh...

MFN • 17 Jun 2024 23:45

KALLELSE TILL ÅRSSTÄMMA I 2CUREX AB (PUBL)

Aktieägarna i 2cureX AB (publ), 559128-0077, kallas härmed till årsstämma måndagen den 1 juli 2024 kl.

MFN • 29 May 2024 14:30

Correction: Revised Financial Calendar Announcement

2cureX AB has revised its financial calendar to align with its strategic shift and previously announced reductions in operational spending.

MFN • 29 May 2024 14:16

Correction: Revised Financial Calendar Announcement

2cureX AB has revised its financial calendar to align with its strategic shift and previously announced reductions in operational spending.

MFN • 29 May 2024 14:10

Revised Financial Calendar Announcement

2cureX AB has revised its financial calendar to align with its strategic shift and previously announced reductions in operational spending.

MFN • 27 May 2024 21:45

2CUREX AB (PUBL) HAS DECIDED TO APPLY FOR A DELISTING OF ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET IN STOCKHOLM – EXPECTED LAST DAY OF TRADING BY END OF JUNE

INSIDE INFORMATION: The Board of Directors of 2cureX AB (publ) (the "Company" or "2cureX") announced on 16 March 2024 an update on the Compa...

MFN • 07 May 2024 10:35

2CUREX AB (PUBL) PROVIDES AN UPDATE ON ITS FINANCIAL POSITION AND CURRENT OPERATIONS

INSIDE INFORMATION: The Board of Directors of 2cureX AB (publ) (the "Company" or "2cureX") has assessed that 2cureX has severe financial cha...

MFN • 16 Mar 2024 17:00

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)

Nedan följer en sammanfattning av de beslut som fattades.

MFN • 29 Feb 2024 16:00

2CUREX PUBLISHES INTERIM REPORT FOR THE FOURTH QUARTER AND FULL YEAR OF 2023 AND FINANCIAL AND STRATEGIC OUTLOOK FOR 2024

2cureX AB (“2cureX”) hereby publishes the interim report for the fourth quarter and full year of 2023 and a financial and strategic outlook ...

MFN • 22 Feb 2024 14:45

KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)

Aktieägarna i 2cureX AB (publ) (”2Curex”), org.nr. 559128-0077, kallas härmed till extra bolagsstämma.

MFN • 12 Feb 2024 14:00

2cureX announces changes to the Board of Directors.

2cureX, a pioneer in the use of 3D tumoroids for predicting cancer treatment efficacy, is implementing significant changes in its governance...

MFN • 04 Jan 2024 08:30

2cureX announces changes to the management

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announces changes to managemen...

MFN • 29 Dec 2023 14:30

2cureX Receives Ethical Approval for Groundbreaking HIPEC Clinical Trial

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, is pleased to announce the app...

MFN • 06 Dec 2023 08:45

2cureX publishes interim report for the third quarter of 2023

2cureX AB (“2cureX”) hereby publishes the interim report for the third quarter of 2023.

MFN • 23 Nov 2023 08:30

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMAN I 2CUREX AB (PUBL)

Nedan följer en sammanfattning av de beslut som fattades.

MFN • 14 Nov 2023 16:00

IndiTreat® Image Uploader gets IVD CE-Mark

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today the CE-Marking...

MFN • 10 Nov 2023 08:45

2cureX participated in “Knæk Cancer” panel discussion.

In connection with the Danish national fundraiser event – Knæk Cancer – the Danish Shareholders' Association arranged a panel discussion foc...

MFN • 30 Oct 2023 08:45

Strategy update: Leapfrogging to the decentralization of IndiTreat® testing through full focus on automation

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announces that it will focus a...

MFN • 26 Oct 2023 18:30

KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)

Aktieägarna i 2cureX AB (publ) (”2Curex”), org.nr. 559128-0077, kallas härmed till extra bolagsstämma.

MFN • 25 Oct 2023 15:46

2cureX advances towards IVD-R compliance by securing a contract with a Notified Body

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today the signature ...

MFN • 11 Oct 2023 12:45

2cureX will be holding its Q3 2023 online presentation with a Q&A session on October 26, 2023 at 20.00 (CET).

2cureX Management will present status on the published goals for 2023 and additional important achievements.

MFN • 03 Oct 2023 09:15

2cureX launches its first two IndiTreat® products CE-marked under the new IVD Regulation

2cureX announced today the launch of two IVD products – IndiTreat® Specimen Collection Kit and IndiTreat® Shipping Container – that have bec...

MFN • 30 Aug 2023 08:30

2cureX publishes interim report for Q2 2023

2cureX AB (“2cureX”) hereby publishes the interim report for the second quarter of 2023.

MFN • 24 Aug 2023 08:30

Invitation to 2cureX Q2 update and Q&A session on July 12, 2023 at 20.00 (CET)

2cureX will be holding its Q2 2023 online presentation with a Q&A session on July 12, 2023 at 20.

MFN • 05 Jul 2023 08:30

Kommuniké från årsstämma i 2cureX AB

Idag, den 25 maj 2023, hölls årsstämma i 2cureX AB.

MFN • 25 May 2023 18:30

2cureX publishes interim report for the first quarter of 2023

2cureX AB (“2cureX”) hereby publishes the interim report for the first quarter of 2023.

MFN • 25 May 2023 08:00

Positive IndiTreat® trial results published in highly recognized scientific journal.

University Hospital of Southern Denmark has had the positive IndiTreat® trial results published in the highly recognized “Journal of Experim...

MFN • 11 May 2023 08:50

Kallelse till årsstämma i 2cureX AB (publ)

Aktieägarna i 2cureX AB (publ), 559128-0077, kallas härmed till årsstämma torsdagen den 25 maj 2023 kl.

MFN • 27 Apr 2023 15:30

2cureX’s CEO Fernando Andreu purchases shares in the company

Fernando Andreu, CEO at 2cureX announces the purchase of 18.

MFN • 25 Apr 2023 16:00

2cureX offentliggör årsredovisning för räkenskapsåret 2022

Copenhagen — April 20, 2023 — Styrelsen och verkställande direktören för 2cureX AB (”2cureX”) offentliggör härmed årsredovisning för räkensk...

MFN • 20 Apr 2023 16:10

2cureX presents preliminary Q1 2023 commercial results.

2cureX will today, at a Q&A session, present commercial results for Q1 2023 and other important achievements in this quarter.

MFN • 12 Apr 2023 14:30

2cureX has received a grant from the Innovation Fund Denmark to support clinical development of a novel IndiTreat® product.

2cureX announced today that it has been awarded a grant of 1.

MFN • 12 Apr 2023 13:00

Invitation to 2cureX Q1 update and Q&A session on April 12, 2023 at 20.00 (CET)

2cureX will have its Q1 2023 online presentation with a Q&A session on April 12, 2023 at 20.

MFN • 10 Apr 2023 08:30

2cureX strengthens its IndiTreat® automation project with a prestigious grant from the German Federal Ministry of Education and Research

2cureX announced today that the company has, together with its technology partners, Hahn-Schickard Institute and the Department of Microsyst...

MFN • 06 Apr 2023 08:30

2cureX announces launch of updated Specimen Collection Set

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today the launch of ...

MFN • 23 Mar 2023 08:30

2cureX publishes interim report for the fourth quarter and full year of 2022

2cureX AB (“2cureX”) hereby publishes the interim report for the fourth quarter and full year of 2022.

MFN • 23 Feb 2023 08:30

Invitation to 2cureX webcast on Year-End Report and latest news on February 23, 2023

2cureX will publish its Year-End/Q4 2022 report on Thursday, February 23, at 08:30 CET.

MFN • 15 Feb 2023 17:30

Kommuniké från extra bolagsstämma i 2cureX AB

Idag, den 10 februari 2023, hölls extra bolagsstämma i 2cureX AB.

MFN • 10 Feb 2023 11:50

KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)

Januari 23 2023

MFN • 23 Jan 2023 20:50

2cureX announces final results regarding 2022 goals

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today the final resu...

MFN • 19 Jan 2023 11:45

2cureX reaches 2022 geographic rollout goal of 20 countries

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today the signature ...

MFN • 20 Dec 2022 08:30

2cureX publishes interim report for the third quarter and first nine months of 2022

2cureX AB (“2cureX”) hereby publishes the interim report for the third quarter and first nine months of 2022.

MFN • 24 Nov 2022 08:00

Invitation to 2cureX webcast and conference call on November 24, 2022

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, will publish its Q3 2022 repor...

MFN • 22 Nov 2022 17:30

2cureX discloses status of 2022 plans, goals for 2023 and its estimates of potential market development in the coming years

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, will hold a Strategy Deep-Dive...

MFN • 14 Nov 2022 08:30

Invitation to 2cureX Strategy Deep-Dive

Market developments and strategic progress in functional drug sensitivity testing

MFN • 01 Nov 2022 13:00

Independent market survey shows great demand for 2cureX product portfolio

2cureX has commissioned independent market research experts 2HMforum to survey GI oncologists as to their ‘Attitude towards drug sensitivity...

MFN • 11 Oct 2022 12:30

Co-inventor of 2cureX patents awarded Nobel Prize in Chemistry

Professor Morten Meldal was yesterday awarded the Nobel Prize in Chemistry.

MFN • 06 Oct 2022 12:15

2cureX terminates liquidity provision service

MFN • 29 Sep 2022 21:00

Change of distribution partner in Portugal

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today that it has ch...

MFN • 19 Sep 2022 08:30

2cureX expands distribution of IndiTreat® to Romania

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, today announced the signature ...

MFN • 01 Sep 2022 08:30

2cureX offentliggör delårsrapport för det andra kvartalet och första halvåret 2022

2cureX AB (”2cureX”) offentliggör härmed delårsrapport för det andra kvartalet och första halvåret 2022.

MFN • 25 Aug 2022 08:30

Kommuniké från extra bolagsstämma i 2cureX

Extra bolagsstämman i 2cureX AB ("2cureX" eller "Bolaget") hölls idag den 8 augusti 2022 varvid aktieägarna fattade följande beslut.

MFN • 08 Aug 2022 14:30

Kallelse till extra bolagsstämma i 2curex AB

Aktieägarna i 2cureX AB, org. nr 559128-0077, ("Bolaget") kallas härmed till extra bolagsstämma måndagen den 8 augusti 2022.

MFN • 20 Jul 2022 13:00

Dr. Raphael Gruber joins 2cureX as new Medical Director

2cureX, a company pioneering the use of 3D micro-tumors (tumoroids) for drug sensitivity testing in patients with cancer, announced today th...

MFN • 01 Jul 2022 08:45

2cureX expands distribution of IndiTreat® to Israel

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, today announced the signature ...

MFN • 28 Jun 2022 08:45

2cureX AB announces share purchase by the company’s Chairman of the Board of Directors and Executive Management

2cureX, a IVD Diagnostic company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announces that ...

MFN • 07 Jun 2022 12:30

Strengthening the IndiTreat® distribution in North Europe

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today that it has re...

MFN • 31 May 2022 08:45

Kommuniké från årsstämma i 2cureX AB

Idag, den 24 maj 2022, hölls årsstämma i 2cureX AB.

MFN • 24 May 2022 16:30

2cureX offentliggör delårsrapport för det första kvartalet 2022

2cureX AB (”2cureX”) offentliggör härmed delårsrapport för det första kvartalet 2022.

MFN • 24 May 2022 12:22

We invite you to join the 2cureX Q1 Report webcast and Q&A session at 15:00 on 24 May, 2022

2cureX will publish its Q1 2022 interim report on Tuesday, 24 May 2022 at 12:00 CET.

MFN • 20 May 2022 13:45

Three IndiTreat® posters have been accepted at ESMO-GI 2022

Three IndiTreat® posters have been accepted at the World Congress on Gastrointestinal Cancer, hosted in Barcelona by the European Society fo...

MFN • 17 May 2022 08:45

2cureX AB nominerar Dr. Michael Schaefer till styrelsen

Dr. Michael Schaefer har föreslagits som ny styrelseledamot i 2cureX AB.

MFN • 12 May 2022 12:00

IGNITE update - Eight hospitals have been enrolled in the program

The enrollment of hospitals in the IGNITE program - 2cureX initiative to speed up the adoption of IndiTreat® - is progressing as planned.

MFN • 11 May 2022 08:45

2cureX presents IndiTreat® clinical results at the Society for Functional Precision Medicine

2cureX is pioneering drug sensitivity testing for the individualized selection of cancer treatment.

MFN • 09 May 2022 08:45

2cureX utser Sedermera Corporate Finance AB till likviditetsgarant för bolagets aktie

2cureX har utsett Sedermera Corporate Finance till bolagets likviditetsgarant.

MFN • 06 May 2022 08:45

Redeye research interview with 2cureX CEO, Fernando Andreu

After the publication of the Annual Report 2021, Redeye’s Equity Research Analyst Eric Nordström interviews 2cureX CEO Fernando Andreu about...

MFN • 05 May 2022 09:30

2cureX offentliggör årsredovisning för räkenskapsåret 2021

Copenhagen — May 3, 2022 — Styrelsen och verkställande direktören för 2cureX AB (”2cureX”) offentliggör härmed årsredovisning för räkenskaps...

MFN • 03 May 2022 20:45

Rättelse: Korrektion till “Kallelse till årsstämma i 2cureX AB” utfärdad den 21 april 2022

Rättelser har gjorts av “Aktieägare som önskar delta i årsstämman ska” ändras från den 17 maj till 16 maj och “Förvaltarregistrerade aktier”...

MFN • 29 Apr 2022 13:30

Korrektion till “Kallelse till årsstämma i 2cureX AB” utfärdad den 21 april 2022

Rättelser har gjorts av “Aktieägare som önskar delta i årsstämman ska” ändras från den 17 maj till 16 maj och “Förvaltarregistrerade aktier”...

MFN • 22 Apr 2022 18:00

Kallelse till årsstämma i 2cureX AB

Aktieägarna i 2cureX AB (publ), 559128-0077, kallas härmed till årsstämma tisdagen den 24 maj 2022 kl.

MFN • 21 Apr 2022 23:00